财务表现 - 公司第二季度末金融资产达31亿美元，同比增长800% [2] - 首次实现正运营现金流230万美元 [4] - 净亏损2000万美元，其中非现金支出2050万美元 [9] - 营收同比增长6%至90万美元 [9] 比特币战略 - 通过私募筹集24亿美元用于比特币国库策略 [3] - 2025年7月累计持有20亿美元比特币及相关证券 [3] - 形成上市公司中最大比特币持仓之一 [3] 业务发展 - 推出Truth+流媒体平台"爱国套餐"订阅服务 [5] - 计划推出包含实用代币的数字钱包奖励系统 [6] - 提交多只ETF注册申请，包括比特币和以太坊ETF [7] - 人工智能功能正在开发中 [6] 运营里程碑 - Truth+平台完成全球推广，已在多数国家上线 [5] - 平台间协同效应显现，订阅者可获跨平台认证 [5] - 法律成本达1500万美元，主要与SPAC合并相关 [9] 公司战略 - 低运营成本和现金消耗率支持扩张计划 [2] - 计划通过并购获取优质资产 [8] - 金融科技品牌TruthFi正在推出 [11]

Palantir will report its second-quarter earnings after the closing bell on Aug. 4.There are probably few investors out there who are more satisfied than those who bought Palantir Technologies (PLTR -2.46%) stock early in its run. The artificial intelligence (AI) company is blowing other stocks out of the water these days, with its stock up 478% in the last year and more than doubling in 2025. Palantir is now one of the world's top 25 most valuable companies, ahead of such blue chip names as Procter & Gamble ...

Grid Dynamics (GDYN -16.44%), a digital engineering and consulting firm, reported its second quarter fiscal 2025 earnings on July 31, 2025. The main news was a GAAP revenue increase to $101.1 million compared to Q2 2024, beating analyst expectations of $100.72 million and slightly exceeding its own midpoint guidance. Non-GAAP earnings per share came in at $0.10, topping the consensus estimate by $0.01. Operating results showed rapid growth in AI and Finance services, with the AI and Data practice accounting ...

美国商务部对Nvidia AI芯片在华销售的审批延迟 - 美国商务部长Howard Lutnick在7月初批准Nvidia等芯片公司恢复向中国销售特定AI芯片 但部门审批流程出现延迟 [1] - Nvidia尚未获得H20 AI芯片对华销售的许可证 主要因商务部内部积压大量申请 [1] - 审批延迟源于商务部内部动荡 包括人员流失及与行业沟通机制失灵 [2] 国家安全因素对芯片出口的影响 - 美国国家安全专家正敦促政府以国家安全为由 限制Nvidia向中国出售H20 AI芯片 [2]

美国商务部对Nvidia AI芯片在华销售的审批延迟 - 美国商务部长Howard Lutnick在7月初已批准Nvidia等芯片公司向中国销售特定AI芯片 但部门内部流程导致实际许可尚未发放[1] - Nvidia目前仍未获得H20 AI芯片对华销售的许可证 主要因商务部内部积压大量申请[1] 审批延迟的内部原因 - 美国商务部面临申请积压问题 主因包括人员流失及与行业沟通机制失效[2] - 部门内部动荡导致审批流程受阻 影响芯片企业的正常商业活动[2] 国家安全因素对芯片贸易的影响 - 国家安全专家正推动特朗普政府以国家安全为由 限制Nvidia向中国出售H20 AI芯片[2] - 当前政治环境使高科技产品出口管制趋于严格 尤其针对AI等敏感技术领域[2]

Key Takeaways TEM gained 34.5% in Q2, outperforming the sector and peers like TXG and SOPH.A $200M AI partnership with AstraZeneca and Pathos is set to drive long-term data monetization for TEM.Despite top-line strength, TEM's valuation premium and lack of profitability may weigh on near-term upside.Tempus AI, Inc. (TEM) is scheduled to report second-quarter 2025 results on Aug. 8.In the last reported quarter, the company’s adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss o ...

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Tevogen has become a recognized name ...

Can the company justify its post-IPO valuation in a competitive, AI-disrupted market?Shares of Figma (FIG 5.43%) exploded this week after its public debut on Thursday. The stock is currently trading 253% higher than its initial public offering (IPO) price as of 3:17 p.m. ET. The extreme leap comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2% amid new tariffs and weak jobs data.Figma, which offers a web-based design platform that is used to create websites and apps, IPOed on Thursday at $33 a share ...

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: Credit: Unsplash/CC0 Public Domain Palantir, the powerful data and AI company with deep ties to US national security bodies, has won a multi-billion-dollar contract to run US Army software and data. The agreement, announced Thursday, consolidates multiple contracts into a single enterprise deal that allows the military to buy ...

Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC. WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development progra ...